- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03150251
Glycemic and Insulinemic Response to Oats Soaked Overnight in Milk Compared to Cream of Rice in Healthy Subjects
May 11, 2017 updated by: PepsiCo Global R&D
One objective of this study is to examine the blood glucose and serum insulin responses over 2hr elicited by oats soaked overnight in milk compared to Cream of Rice soaked overnight in milk and compared to Cream of Rice cooked in water.
In addition a second objective of the study is to measure subjective ratings of hunger and fullness under the same conditions.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
40
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Toronto, Canada
- Glycemic Index Laboratories
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
Male or non-pregnant females, 18-75 years of age, inclusive
- Body mass index (BMI) between 20.00 and 34.99 kg/m² inclusive at screening (visit 1).
- Willing to maintain habitual diet, physical activity pattern, and body weight throughout the trial and to refrain from smoking for 12hr prior to each visit.
- Willing to maintain current dietary supplement use throughout the trial. On test days, subject agrees not to take any dietary supplements until dismissal from the GI labs. Failure to comply will result in a rescheduled test visit.
- Normal fasting serum glucose (<7.0mmol/L capillary corresponding to whole blood glucose <6.3mmol/L).
- Willing to abstain from alcohol consumption and avoid vigorous physical activity for 24 h prior to all test visits.
- Absence of health conditions that would prevent fulfillment of study requirements as judged by the Investigator on the basis of medical history.
- Understanding the study procedures and willing to provide informed consent to participate in the study and authorization to release relevant protected health information to the study investigator.
Exclusion Criteria:
- Failure to meet any one of the inclusion criteria
- Known history of AIDS, hepatitis, a history or presence of clinically important endocrine (including Type 1 or Type 2 diabetes mellitus), cardiovascular (including, but not limited to, atherosclerotic disease, history of myocardial infarction, peripheral arterial disease, stroke), pulmonary, biliary or GI disorders.
- Use of medications known to influence carbohydrate metabolism, including, but not limited to adrenergic blockers, diuretics, thiazolidinediones, metformin and systemic corticosteroids within 4 weeks of the screening visit, or with any condition which might, in the opinion of Dr. Wolever, the president of GI Testing, either: 1) make participation dangerous to the subject or to others, or 2) affect the results.
- Major trauma or surgical event within 3 months of screening.
- Unwillingness or inability to comply with the experimental procedures and to follow GI Labs safety guidelines.
- Known intolerance, sensitivity or allergy to any ingredients in the study products.
- Extreme dietary habits, as judged by the Investigator (i.e. Atkins diet, very high protein diets, etc.).
- Uncontrolled hypertension (systolic blood pressure ≥160 mm Hg or diastolic blood pressure ≥100 mm Hg as defined by the average blood pressure measured at screening.
- Change in body weight of >3.5kg within 4 weeks of the screening visit.
- Presence of any signs or symptoms of an active infection within 5 d prior to any test visit. If an infection occurs during the study period, test visits should be rescheduled until all signs and symptoms have resolved and any treatment (i.e. antibiotic therapy) has been completed at least 5 d prior to each test visit.
- History of cancer in the prior two years, except for non-melanoma skin cancer.
- Recent history (within 12 months of screening) or strong potential for alcohol or substance abuse. Alcohol abuse is defined as > 14 drinks per week (1 drink=12 oz beer, 5 oz wine, or 1.5 oz distilled spirits).
- Exposure to any non-registered drug product within 30 d prior to screening.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Overnight Oats
40 g of overnight oats
|
Consumption of one cereal in the beginning of each visit
Other Names:
|
PLACEBO_COMPARATOR: Soaked Cream of Rice
28.8 cream of rice
|
Consumption of one cereal in the beginning of each visit
Other Names:
|
PLACEBO_COMPARATOR: Cooked Cream of Rice
28.8 cooked cream of rice
|
Consumption of one cereal in the beginning of each visit
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incremental area under the blood glucose curve
Time Frame: 0-2 hours
|
0-2 hours
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
incremental areas under the curve of blood glucose from 2-3h
Time Frame: 2-3 hours
|
2-3 hours
|
incremental areas under the curve of blood glucose from 0-3h
Time Frame: 0-3 hours
|
0-3 hours
|
incremental areas under the curve of insulin serum 0-2 hours
Time Frame: 0-2 hours
|
0-2 hours
|
incremental areas under the curve of insulin serum 2-3 hours
Time Frame: 2-3 hours
|
2-3 hours
|
incremental areas under the curve of insulin serum 0-3 hours
Time Frame: 0-3 hours
|
0-3 hours
|
peak concentrations and peak rises of glucose and insulin
Time Frame: 0-3 hours
|
0-3 hours
|
blood glucose and insulin concentrations and increments at each time point over a 3hr period
Time Frame: 0-3 hours
|
0-3 hours
|
netAUC of the curves for fullness, hunger, desire to eat, prospective consumption and average appetite over 0-2hr and 0-3hr
Time Frame: 0-2 hour and 0-3 hours
|
0-2 hour and 0-3 hours
|
self reports of fullness, hunger, desire to eat, prospective consumption and average appetite at each point in time via questionnaires
Time Frame: 3 hours post consumption
|
3 hours post consumption
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
November 28, 2016
Primary Completion (ACTUAL)
March 31, 2017
Study Completion (ACTUAL)
April 15, 2017
Study Registration Dates
First Submitted
May 10, 2017
First Submitted That Met QC Criteria
May 11, 2017
First Posted (ACTUAL)
May 12, 2017
Study Record Updates
Last Update Posted (ACTUAL)
May 12, 2017
Last Update Submitted That Met QC Criteria
May 11, 2017
Last Verified
May 1, 2017
More Information
Terms related to this study
Other Study ID Numbers
- PEP-1610
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glycemic, Insulinemic, Subjective Appetite Responses
-
PepsiCo Global R&DCompletedGlycemic | Insulinemic | Subjective Hunger ResponsesCanada
-
University of BirminghamCompletedNeural Responses | Appetite Hormones | Subjective Appetite SensationsUnited Kingdom
-
University Hospital, Basel, SwitzerlandCompletedGastrointestinal Hormones | Glycemic Control | Appetite | Satiation | Reward Responses | Emotional StateSwitzerland
-
Ryerson UniversityCompletedGlycemic Control | Subjective AppetiteCanada
-
PepsiCo Global R&DCompletedGlycemic and Insulinemic ResponseCanada
-
PepsiCo Global R&DDSM Nutritional Products, Inc.Completed
-
PepsiCo Global R&DCompletedGlycemic Response | Insulinemic Response | Subjectvie HungerCanada
-
Azienda Ospedaliera Specializzata in Gastroenterologia...CompletedHealthy Subjects | Glycemic Response | Insulinemic ResponseItaly
-
KU LeuvenCompletedPostprandial Glycemic ResponsesBelgium
-
PepsiCo Global R&DCompletedGlycemic Response | Insulinemic Response | Subject Hunger ResponseCanada
Clinical Trials on Cereal - oats
-
Glycemic Index Laboratories, IncPepsiCo Global R&D; Applied Statistics and ConsultingCompletedDiabetes MellitusCanada
-
Democritus University of ThraceActive, not recruitingCholesterol LevelsGreece
-
Laboratorios OrdesaMinisterio de Ciencia e Innovación, SpainUnknownGastrointestinal Disorder | Immunologic Diseases in ChildrenSpain
-
Quadram Institute BioscienceClinical Research and Trials Unit (Norfolk & Norwich University Hospital,...CompletedMetabolic SyndromeUnited Kingdom
-
McMaster UniversityRecruitingCeliac Disease | Gluten Sensitivity | Gluten Enteropathy | Gluten AllergyCanada
-
Alfred Rusescu Institute for Mother and Child CareThe National Research and Development Institute for Alimentary Bioresources...Completed
-
Harokopio UniversityNational and Kapodistrian University of AthensCompletedOverweight and ObesityGreece
-
Frank GreenwayPepsiCo Global R&D; Quaker Oats CompanyCompletedFood Intake | SatietyUnited States
-
Hero Institute for Infant NutritionUniversidad de Murcia; Hospital Universitario Virgen de la Arrixaca; Quantum...CompletedInfant Nutrition SciencesSpain